Speculation Heats Up on Amarin (AMRN) After Sales Force Hiring Delayed
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amarin (AMRN) Vascepa Pricing Leak?
December 3, 2012 3:21 PM ESTAmarin Corp Plc (NASDAQ: AMRN) investors were buzzing earlier today after a website inadvertently posted prices for Vascepa that appeared to be relatively low compared to market expectations.
GoodRx was showing prices of $51 for 30 capsules of 1g Vascepa (see below), although... More
Amarin (AMRN) Delays Hiring Vascepa Sales Reps Until Early December
November 29, 2012 7:58 AM ESTAmarin Corporation plc (Nasdaq: AMRN) previously guided that it would make a decision to hire prospective sales representatives as part of its continued Vascepa commercialization preparations before the end of November 2012.
Amarin now expects to make this decision in the first half of... More
